Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

Acquisitions - Narrative (Details)					1 Months Ended	2 Months Ended	3 Months Ended			8 Months Ended	9 Months Ended		10 Months Ended
Acquisitions - Narrative (Details)	Sep. 25, 2018 shares	Sep. 24, 2018 USD ($) therapy $ / shares shares	Feb. 16, 2018 USD ($)	Nov. 17, 2017 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares	Mar. 31, 2018 USD ($)	Sep. 30, 2018 USD ($) $ / shares	Jun. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) $ / shares	Sep. 30, 2018 USD ($) $ / shares	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) $ / shares	Aug. 17, 2018 $ / shares
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \| $ / shares		$ 0.001			$ 0.001		$ 0.001			$ 0.001	$ 0.001		$ 0.001	$ 0.001
Goodwill					$ 14,292,282		$ 16,411,123			$ 16,411,123	$ 16,411,123		$ 16,411,123
Impairment of intangible assets							159,687		$ 0		1,861,562	$ 0
Cost of product sales							3,111,290		$ 0		5,397,872	$ 0
Avadel
Business Acquisition [Line Items]
Cash			$ 1
Fair value of debt assumed			(15,075,000)
Contingent consideration			7,900,000
Goodwill			$ 3,778,001
Goodwill tax deductible period			15 years
Pro forma adjustment operating expenses							300,000
Pro forma adjustment cost of sales							200,000
Pro forma adjustment sales and marketing expense							100,000
Inventory						$ 300,000		$ (1,831,000)
Fair value of consideration transferred			$ 1
Cost of product sales										100,000
TRx
Business Acquisition [Line Items]
Cash				$ 18,900,000
Contingent consideration				1,366,633
Goodwill				$ 12,633,122
Inventory					$ 200,000								0
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) \| shares				7,534,884
Shares issued for purchase of business (in shares)				$ 8,514,419
Shares issued upon closing (in shares) \| shares				5,184,920
Contingent shares issuable as part of acquisition (in shares) \| shares				2,349,968
Goodwill, expected tax deductible amount				$ 8,700,000
General and administrative expenses													1,000,000
Other income													300,000
Impairment of intangible assets													200,000
Intangible amortization expense													100,000
Income tax expense (benefit)													100,000
Fair value of consideration transferred				$ 28,781,052
Cost of product sales							200,000
General and administrative \| Avadel
Business Acquisition [Line Items]
Transaction costs							100,000			100,000	100,000		100,000
PAI Sales & Marketing Agreement \| TRx
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, weighted average useful life (in years)				2 years
Metafolin \| Acquired product marketing rights \| TRx
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, weighted average useful life (in years)				15 years
Millipred \| Acquired product marketing rights \| TRx
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, weighted average useful life (in years)				4 years
Ulesfia \| Acquired product marketing rights \| TRx
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, weighted average useful life (in years)
Nonrecurring \| Level 3 \| PAI Sales & Marketing Agreement \| TRx
Business Acquisition [Line Items]
Fair value of sales and marketing agreement							$ 0			$ 0	$ 0		$ 0
Ichorion
Business Acquisition [Line Items]
Consideration issued (in shares) \| shares	5,800,000	5,800,000
Contingent consideration		$ 15,000,000
Fair value of shares issued		20,000,000
Intangible assets		$ 18,700,000
Number of preclinical therapies \| therapy		3
Cash acquired		$ 1,600,000
Transaction costs		200,000
Ichorion \| Assembled Workforce
Business Acquisition [Line Items]
Intangible assets		$ 200,000
Useful life (in years)		2 years